Biogen Shifts Strategy to Early-Stage Drug Research
The company initiated five new clinical trials in 2026 as part of a pivot toward internal research and development.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Do you trust that focusing on early-stage drug development improves the reliability of new medicine?
Biogen initiated five Investigational New Drug applications in 2026, marking a shift toward early-stage research and development. The firm completed an overhaul of its development strategy following a three-year period without new drug trials.
Why it matters
The company shifted its strategy to focus on early-stage development, which the CEO identified as the most capital-efficient stage to introduce new assets. This pivot seeks to modernize the company by managing portfolios of opportunities rather than evaluating assets individually.
Biogen now targets drugs ranging from preclinical development to phase 1b. The company currently maintains a target of 20 programs in its early-stage pipeline.
The players
Biogen
Biogen is a biotechnology company that has operated for 48 years.
The details
Biogen expanded its capabilities by acquiring several firms, including Apellis Pharmaceuticals, RayThera, HI-BIO, Alcyone Therapeutics, and Reata Pharmaceuticals, between 2023 and 2026. The company intends to advance six new programs, including three molecular entities, as part of this broader strategy.
Timeline
Between 2023 and 2026, Biogen acquired multiple biotech and drug companies.
On October 28, 2026, the CEO discussed the research and development strategy during a third-quarter earnings call.
The Tech Race
This strategic pivot positions the firm against competitors who are increasingly prioritizing early-stage molecular research. By shifting away from individual asset evaluation, Biogen attempts to replace older models with a portfolio-based management system.
The move toward early-stage development could increase the variety of experimental treatment options available to patients in the long term. Investors and observers should note that this strategy aims to improve capital efficiency within the pharmaceutical sector.
The takeaway
Biogen is moving toward a more sustainable growth model by targeting early-stage drug development rather than relying solely on mature assets. This approach suggests a broader trend in the biotech industry of prioritizing portfolio management to mitigate risk and maximize capital efficiency.
Further reading
For more information on current industry trends, visit the Biotech section.
Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.
Live Poll
Do you trust that focusing on early-stage drug development improves the reliability of new medicine?
